

Ortho Clinical Diagnostics Conflict Mineral Policy Statement

Ortho Clinical Diagnostics (“Ortho”) is a leading global provider of in vitro diagnostics products. We have an established history for providing high-quality products and services to the global clinical laboratory and immunohematology communities.

Protecting the environment and advancing sustainability go hand-in-hand with our purpose of improving and saving lives through diagnostics. We are committed to operating in a legal and ethical manner that supports the environmental health of the communities in which we operate and the sustainability of the planet. In our operations, we focus our environmental efforts on reducing waste and energy consumption while generating clean energy at our global facilities and incorporating environmentally friendly practices into our product manufacturing and packaging.

On August 22, 2012, the U.S. Securities and Exchange Commission (“SEC”) adopted rules implementing disclosure requirements related to "conflict minerals," as directed by Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the “Dodd-Frank Act”). The term “Conflict Minerals” in this context refers to specific minerals originating from mines controlled by armed groups in the Democratic Republic of the Congo or adjoining countries. These Conflict Minerals (also known as 3TGs) are:

- tin (cassiterite);
- tungsten (wolframite);
- tantalum (columbite-tantalite or coltan); and
- gold.

Ortho complies with the Organisation for Economic Co-operation and Development (“OECD”) Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High-Risk Areas, as well as the applicable requirements of Section 1502 of the Dodd-Frank Act. We are committed to sourcing components and materials from companies that share our values regarding respect for human rights, integrity, and environmental responsibility. To meet this objective, Ortho:

- Will comply with the annual disclosure requirements of the Dodd-Frank Act.
- Train our procurement employees on our obligations under the Conflict Minerals rules.
- Requires our suppliers to conduct due diligence on the origin and chain of custody of minerals in accordance with OECD guidance to help ensure that smelters and refiners in their supply chain sourcing minerals from conflict-affected and high-risk areas are either in compliance with the Responsible Minerals Assurance Process assessment protocols or are actively working towards becoming in compliance.

- Routinely request our direct material suppliers to submit a report consistent with the Responsible Minerals Initiative Conflict Minerals Reporting Template and review their submissions against conformance to the Responsible Minerals Initiative; and
- If one of our suppliers has challenges in complying with our expectations, Ortho will work diligently with that supplier to address the concerns.

Upon request, Ortho will provide our customers with Conflict Mineral Reporting (CMRT) data we collected from our supply base, enabling customers to meet their own respective SEC reporting requirements.

If you have specific questions or would like additional information, please email conflict-minerals@orthoclinicaldiagnostics.com.



Marwan Fathallah

Head Of Quality, Regulatory, Compliance, Clinical & Medical Affairs • Quality Assurance & Quality Compliance • Operations



Samantha Betancourt

VP, Global Supply Chain And External Operations